GCG

GC Genome is a clinical genome analysis company in South Korea. It offers hereditary cancer, tissue and liquid biopsy genetic, blood cancer, and homologous recombination deficiency tests under the Green Plan names.

Its portfolio also includes Guardant360, a blood genetic profiling test, Guardant Reveal, a liquid biopsy microscopic residual disease detection and recurrence monitoring test, and genetic rare disease testing services for chromosomal microarray, targeted exome sequencing, whole exome sequencing, and diagnostic genome sequencing Ai-CANCERCH, an AI algorithm-based multi-cancer early screening test.

Its portfolio also includes Jins Sketch, a genetic test for personalized nutrition, Genome Health and Risk Screen that identifies various disease-susceptibility genes, Green Biome for human symbiotic microorganism genetic analysis service, Genome Screen, an optimal genetic test for preemptive action, Telorisk, an indicator of biological age, and drug compatibility DNA test.

Additionally, it offers G-NIPT, a noninvasive fetal chromosomal abnormality screening test. Its portfolio also includes Prenatal CMA, a diagnostic test for fetal chromosomal abnormalities with higher diagnostic value, i-screen for newborn genetic screening, and dd-cfDNA, a single nucleotide polymorphism test of cell-free nucleic acid derived from organ transplant donors. Founded in 2013, the company is based in Yongin-si, South Korea.